|
|
![]() |
Go to MPEP - Table of Contents
2424.02 Sequence Listing Numeric Identifiers - 2400 Biotechnology
2424.02 Sequence Listing Numeric Identifiers
37 CFR 1.823(b) sets forth the order and presentation of the items of information in the Sequence Listing. Each item of information in the Sequence Listing must include the appropriate numeric identifier and its accompanying information as shown in the table below. Each item of information must begin on a new line with the numeric identifier enclosed in angle brackets. The submission of those items of information designated with an "M" is mandatory. The submission of those items of information designated with an "O" is optional. Numeric identifiers <110> through <170> must be set forth at the beginning of the Sequence Listing.
The following table illustrates the numeric identifiers. See MPEP § 2431 for a sample Sequence Listing.
Numeric Identifier Definition Comments and format Mandatory (M) or Optional (O) <110> Applicant...................... Preferably max. of 10 names; one name per line; preferable format: Surname, Other Names and/or Initials. M. <120> Title of Invention.......... ............................................................. M. <130> File Reference............... Personal file reference......................... M when filed prior to assignment or appl. number <140> Current Application Number. Specify as: US 07/999,999 or PCT/US96/99999. M, if available. <141> Current Filing Date....... Specify as: yyyy-mm-dd...................... M, if available. <150> Prior Application
Number.Specify as: US 07/999,999 or PCT/US96/99999. M, if applicable include priority documents under 35 U.S.C. 119 and 120 <151> Prior Application Filing Date. Specify as: yyyy-mm-dd ..................... M, if applicable <160> Number of SEQ ID NOs. Count includes total number of SEQ ID NOs................................................. M. <170> Software....................... Name of software used to create the Sequence Listing. O. <210> SEQ ID NO:#:.............. Response shall be an integer representing the SEQ ID NO shown. M. <211> Length........................... Respond with an integer expressing the number of bases or amino acid residues. M. <212> Type.............................. Whether presented sequence molecule is DNA, RNA, or PRT (protein). If a nucleotide sequence contains both DNA and RNA fragments, the type shall be "DNA." In addition, the combined DNA/ RNA molecule shall be further described in the <220> to <223> feature section. M. <213> Organism...................... Scientific name, i.e. Genus/ species, Unknown or Artificial Sequence. In addition, the "Unknown" or "Artificial Sequence" organisms shall be further described in the <220> to <223> feature section. M. <220> Feature.......................... Leave blank after <220>. <221-223> provide for a description of points of biological significance in the sequence. M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGANISM is "Artificial Sequence" or "Unknown"; if molecule is combined DNA/RNA. <221> Name/Key..................... Provide appropriate identifier for feature, preferably from WIPO Standard ST.25 (1998), Appendix 2, Tables 5 and 6. M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence. Numeric Identifier Definition Comments and format Mandatory (M) or Optional (O) <222> Location........................ Specify location within sequence; where appropriate state number of first and last bases/amino acids in
feature.M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence. <223> Other Information......... Other relevant information; four lines maximum............................................. M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGANISM is "Artificial Sequence" or "Unknown"; if molecule is combined DNA/RNA. <300> Publication Information Leave blank after <300> O. <301> Authors......................... Preferably max. of ten named authors of publication; specify one name per line; preferable format: Surname, Other Names and/or Initials. O. <302> Title............................... ............................................................. O. <303> Journal.......................... ............................................................. O. <304> Volume ......................... ............................................................. O. <305> Issue ............................. ............................................................. O. <306> Pages ............................ ............................................................. O. <307> Date.............. Journal date on which data published; specify as yyyy- mm-dd, MMM-yyyy or Season- yyyy. O. <308> Database Accession Number. Accession number assigned by database including database name. O. <309> Database Entry Date........ Date of entry in database; specify as yyyy-mm-dd or MMM-yyyy. O. <310> Patent Document Number. Document number; for patent-type citations only. Specify as, for
example, US 07/ 999,999.O. <311> Patent Filing Date.............. Document filing date, for patent-type citations only; specify as yyyy-mm-dd. O. <312> Publication Date................ Document publication date, for patent-type citations only; specify as yyyy-mm-dd. O. <313> Relevant
Residues............FROM (position) TO (position)........... O. <400> Sequence....................... SEQ ID NO should follow the numeric identifier and should appear on the line preceding the actual sequence. M.
The Inventors Assistance Center is available to help you on patent matters.Send questions about USPTO programs and services to the USPTO Contact Center (UCC). You can suggest USPTO webpages or material you would like featured on this section by E-mail to the webmaster@uspto.gov. While we cannot promise to accommodate all requests, your suggestions will be considered and may lead to other improvements on the website. |
|
Go to MPEP - Table of Contents